Literature DB >> 12621691

Serum concentrations of sCD30 and sCD40L in patients with malignant bone tumours.

Gerold Holzer1, Thomas Pfandlsteiner, Harald Blahovec, Klemens Trieb, Rainer Kotz.   

Abstract

The aim of this study was to evaluate serum levels of both soluble CD30 (sCD30) and soluble CD40 ligand (sCD40L) in patients with malignant bone tumours and to determine their ability to serve as serum markers. Sera of 31 patients were taken at the time of diagnosis, analysed by ELISA, and the results were correlated with clinical features and compared with healthy controls. Soluble CD30 and sCD40L levels were significantly higher in all patient groups than in the healthy controls. Soluble CD30 levels showed statistically significant differences between high malignant osteosarcoma and Ewing sarcoma (P = 0.015), whereas no statistically significant correlation was seen between different types of tumours and sCD40L levels. Soluble CD30 and sCD40L seem to be of diagnostic value in osteosarcoma and Ewing sarcoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621691     DOI: 10.1046/j.1563-258x.2003.02008.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  19 in total

1.  Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy.

Authors:  R Gerli; O Bistoni; C Lunardi; R Giacomelli; C Tomassini; P Biagini; C Pitzalis
Journal:  Rheumatology (Oxford)       Date:  1999-12       Impact factor: 7.580

2.  Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.

Authors:  A Younes; V Snell; U Consoli; K Clodi; S Zhao; J L Palmer; E K Thomas; R J Armitage; M Andreeff
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

3.  Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis.

Authors:  M Pfreundschuh; C Pohl; C Berenbeck; J Schroeder; W Jung; R Schmits; A Tschiersch; V Diehl; A Gause
Journal:  Int J Cancer       Date:  1990-05-15       Impact factor: 7.396

4.  [EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study)-- preliminary results].

Authors:  M Paulussen; S Ahrens; G Braun-Munzinger; A W Craft; B Dockhorn-Dworniczak; W Dörffel; J Dunst; B Fröhlich; U Göbel; M Häussler; T Klingebiel; E Koscielniak; U Mittler; C Rübe; W Winkelmann; P A Voûte; A Zoubek; H Jürgens
Journal:  Klin Padiatr       Date:  1999 Jul-Aug       Impact factor: 1.349

5.  Expression of Ki-1 antigen (CD30) in mesenchymal tumors.

Authors:  G Mechtersheimer; P Möller
Journal:  Cancer       Date:  1990-10-15       Impact factor: 6.860

6.  CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role.

Authors:  R Gerli; C Pitzalis; O Bistoni; B Falini; V Costantini; A Russano; C Lunardi
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

7.  Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells.

Authors:  P L Lollini; L Landuzzi; F Frabetti; I Rossi; G Nicoletti; K Scotlandi; M Serra; N Baldini; C De Giovanni; P Nanni
Journal:  Clin Cancer Res       Date:  1998-08       Impact factor: 12.531

8.  Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.

Authors:  G Nadali; F Vinante; H Stein; G Todeschini; C Tecchio; L Morosato; M Chilosi; F Menestrina; M C Kinney; J P Greer
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

9.  A system for the surgical staging of musculoskeletal sarcoma.

Authors:  W F Enneking; S S Spanier; M A Goodman
Journal:  Clin Orthop Relat Res       Date:  1980 Nov-Dec       Impact factor: 4.176

10.  High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints.

Authors:  R Gerli; C Muscat; O Bistoni; B Falini; C Tomassini; E Agea; R Tognellini; P Biagini; A Bertotto
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

View more
  2 in total

1.  Triggering CD40 on endothelial cells contributes to tumor growth.

Authors:  Claudia Chiodoni; Manuela Iezzi; Cristiana Guiducci; Sabina Sangaletti; Isabella Alessandrini; Chiara Ratti; Francesca Tiboni; Piero Musiani; D Neil Granger; Mario P Colombo
Journal:  J Exp Med       Date:  2006-10-16       Impact factor: 14.307

2.  Obesity Does Not Exacerbate the Protumorigenic Systemic Environment in Sarcoma Subjects.

Authors:  Claire M Buchta; Shannon K Boi; Benjamin J Miller; Mohammed M Milhem; Lyse A Norian
Journal:  Immunohorizons       Date:  2017-06-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.